Call for Abstract
13th International Conference on Bio Banking and Tissue Preservation , will be organized around the theme “Present and Future : Techniques for sustainable Bio banking and tissue preservation in the digital era””
Bio Banking 2019 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Bio Banking 2019
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
- Track 1-1Other Diseases
- Track 1-2Engraftment
- Track 1-3Manufacturing
- Track 1-4Successful transplants
- Track 1-5Manufacturing
An amniotic stem cell bank is a facility that stores stem cells derived from amniotic fluid for future use. Stem cell samples in private banks are stored specifically for use by the individual person from whom such cells have been collected and the banking costs are paid by such person.
- Track 2-1Umbilical Cord Blood Banks
- Track 2-2Hematopoietic Stem Cell and Potential Non-Hematopoietic and Stem Cells
- Track 2-3Amniotic Stem Cell Bank
Many of us might have observed that the tail of a lizard, if cut, can grow efficiently all over again. This is an example of tissue regeneration. Like lizards, in many other animals including human’s tissue regrowth can be observed. By definition it means regrowth of damaged or affected tissue from rest of the part. The initial step is rearrangement of pre-existing tissue followed by de-differentiation and trans-differentiation of the cells. This involves cells called stem cells which have the potential to regenerate themselves. There are intrinsic signals that activate stem cells to undergo regeneration when needed. There are amazing instances of tissue regeneration, for example heart regeneration in zebra fish. In humans, liver cells can regenerate themselves. But there are many cells and tissue that lack this ability. To help humans fight tissue damages in a better way tissue regeneration needs immediate attention. Researchers across the globe should come together to unleash the mystery of the signals and genetics that trigger regeneration in some tissues.
- Track 3-1Animal models of tissue regeneration
- Track 3-2Molecular fundamentals of regeneration
- Track 3-3Intrinsic Tissue regeneration
- Track 3-4Guided Tissue Regeneration
- Track 3-5Human tissue regeneration: Challenges in in-vivo and in-vitro regeneration
- Track 3-6In silico Tissue engineering
Stem Cells are undifferentiated cells that have the potency to regenerate and differentiate into cells of specific lineage. They are classified as oligo potent, pluripotent, totipotent cells based on the different types of cells formed after differentiation. The broader classification includes embryonic stem cells and adult stem cells. Mesenchymal stem cell (MSC) is a variant of adult stem cell that gives rise to osteoblast, adipocytes and chondrocytes. MSC transplantation for tissue engineering has grabbed attention due to its immunosuppressive features. It is now in use to regenerate tissues of kidney, liver, heart; bone etc. Stem cell culture forms the base for the tissue engineering approach. A minor change in the culture environment may lead to altered potency of the cells. So special reagents and media are required. Moreover, 3D culture techniques and CRISPR genome editing technology are also in market.
- Track 4-1Cancer Stem Cells
- Track 4-2Mesenchymal Stem Cells
- Track 4-3Stem Cell Therapy
- Track 4-4Induced Pluripotent Stem cells (IPSC)
Umbilical cord blood despite collected in very small volume, it contains millions of a specific type of the adult stem cell that can go on to form the blood and immune system. Because cord blood and cord tissue are each rich in a different type of stem cell, it makes sense that they would serve as treatments for different diseases or conditions. Both the hematopoietic stem cells in the cord blood and the mesenchymal stem cells in the cord tissue can be used to help heal, regenerate, or otherwise treat a variety of conditions, but the conditions and diseases that they treat don’t often overlap. The potential future use of mesenchymal stem cells, like those in cord tissue, is still being reviewed in clinical trials, but the outcomes thus far have been very promising. They are being used to treat heart and kidney disease, Amyotrophic Lateral Sclerosis (ALS), autoimmune disease, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, wound healing and even sports injuries. Cord blood is a proven treatment for more than 80 diseases, and there are a number of exciting clinical trials underway for its use in other treatments. Cord tissue has an exciting future and shows great potential for the treatment of conditions which were once untreatable.
- Track 5-1Inherited metabolic disease
- Track 5-2Neonatal hypoxic-ischemic encephalopathy
- Track 5-3Neonatal hypoxic-ischemic encephalopathy
- Track 5-4Cerebral palsy
- Track 5-5Juvenile diabetes mellitus
- Track 5-6Cord blood transplantation
- Track 5-7Adoptive cell therapy
In native state, majority of the cells (except the red blood cells) in our body are anchorage dependent and remain attached to a rigid support called extracellular matrix (ECM). It plays a key role in providing structural support to the cells and adds to the mechanical properties of tissues. It also helps the cells respond to the signals of micro-environment. Due to highly dynamic properties of ECM, it cannot be mimicked. But, scientists have developed biomaterials and biopolymers that can act as ECM and serve the similar functions in engineered tissues. The biomaterials should have some features like bioactivity, porosity, bio-compatibility etc. There are four scaffolding approaches as of now: 1) Pre-made porous scaffolds for cell seeding 2) Decellularized extracellular matrix for cell seeding 3) Confluent cells with secreted extracellular matrix 4) Confluent cells with secreted extracellular matrix. Preparation of scaffolds is a challenging task. Various approaches are Nano-fiber self-assembly, Solvent casting and particulate leaching, Gas foaming, Laser-assisted bio printing etc.
- Track 6-1Cell seeding
- Track 6-2Hydrogels
- Track 6-3Cell encapsulation and microencapsulation
- Track 6-4Biopolymers
- Track 6-5Biomaterials
- Track 6-6Cell sheets
Globally three types of cord blood banks: public, private and hybrid are available. Private Banks captured the largest revenue share owing to the high cost associated with collection and storage of cord blood unit charged to parents. Moreover, the marketing activities practiced by the private players are resulting in the increased customer base of private players compared to public banks. Considering all the above mentioned factors together, private banking service segment was leading the global market.
- Track 7-1Management & Administration
- Track 7-2Market for Cord Blood
- Track 7-3Sustainability
- Track 7-4Motivating Cord Blood Donation
- Track 7-5Patient groups and clinical trials
- Track 7-6Cord Blood Insurance
- Track 7-7Using AI in hospitals
- Track 7-8Cord blood bank models
- Track 7-9Banking Processes
The collection of tissue from one individual for therapeutic use in another individual involves not only technical and medical issues, but also ethical and legal issues. Donors of cord blood are not merely depositing the leftover by-products of the birth process with interested researchers and physicians; rather, they are making a choice to do something that may potentially benefit either unknown beneficiaries or members of their own families. Pregnant women receive a great deal of information sometimes conflicting about the donation process and the consequences of different types of banking. It is important to disclose a lot of information to the potential donor, including who has access to the cord blood once it is donated, where it is stored, how it is stored, and how the donor’s privacy is protected.
- Track 8-1Informed consent of donors
- Track 8-2Disclosure of information regarding screening and other risks
- Track 8-3Maintenance of donor records/patient privacy
For most parents, banking their baby’s umbilical cord blood and cord tissue is a new experience. At first glance, the process may seem difficult; however, it is actually very simple for the parents. Most of the mothers are worried about how the delivery will go and don’t want to also be worried about the details of collecting, processing and cryopreserving their baby’s cord blood. Generally, the healthcare provider and the cord blood bank do most of the work.
The banking process can be broken down into the following five steps:
- Track 9-1Enrollment
- Track 9-2Collection
- Track 9-3Transportation
- Track 9-4Testing and Processing
- Track 9-5Preservation